Patents by Inventor Albert TORRI

Albert TORRI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFYING BINDING MOLECULES TO MINIMIZE PRE-EXISITING INTERACTIONS
    Publication number: 20230266333
    Abstract: The present disclosure is directed towards modifying binding molecules in order to minimize pre-existing binding interactions, including binding molecules engineered to minimize or mitigate background reactivity in a sample matrix caused by drug non-specific binding interactions.
    Type: Application
    Filed: September 19, 2022
    Publication date: August 24, 2023
    Inventors: Giane Oliveira SUMNER, Jihua CHEN, Michael PARTRIDGE, Albert TORRI, Manoj RAJADHYAKSHA
  • ASSAYS TO QUANTITATE DRUG AND TARGET CONCENTRATIONS
    Publication number: 20230110651
    Abstract: The present invention generally pertains to methods of determining concentrations of drugs and their targets. In particular, the present invention, in part, pertains to use of a mild acidic assay condition to determine total drug and total target concentrations to mitigate either target interference or drug interference. The present invention also discloses a free target assay using a capture agent that has a lower affinity with a much slower association and dissociation rate compared to the drug.
    Type: Application
    Filed: September 28, 2022
    Publication date: April 13, 2023
    Inventors: Jihua Chen, Kimberly Kendra, Stacey Shank, Lisa DeStefano, Matthew Andisik, Michael Partridge, Albert Torri, Giane Oliveira Sumner
  • Modifying binding molecules to minimize pre-exisiting interactions
    Patent number: 11448651
    Abstract: The present disclosure is directed towards modifying binding molecules in order to minimize pre-existing binding interactions, including binding molecules engineered to minimize or mitigate background reactivity in a sample matrix caused by drug non-specific binding interactions.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: September 20, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Giane Oliveira Sumner, Jihua Chen, Michael Partridge, Albert Torri, Manoj Rajadhyaksha
  • TARGET INTERFERENCE MITIGATION IN ANTI-DRUG ANTIBODY ASSAY
    Publication number: 20210293811
    Abstract: The present invention provides methods and systems to detect, quantify or characterize anti-drug antibodies which are induced by the administration of pharmaceutical products. The methods and systems include the use of a binding partner of a target and/or a co-factor to improve the detection of anti-drug antibodies in serum samples in the presence of soluble targets based on competitive target binding. The methods and systems also include the use of immuno-depletion to improve the detection.
    Type: Application
    Filed: March 16, 2021
    Publication date: September 23, 2021
    Inventors: Jihua Chen, Kimberly Kendra, Albert Torri, Giane Oliveira Sumner
  • MODIFYING BINDING MOLECULES TO MINIMIZE PRE-EXISITING INTERACTIONS
    Publication number: 20200018754
    Abstract: The present disclosure is directed towards modifying binding molecules in order to minimize pre-existing binding interactions, including binding molecules engineered to minimize or mitigate background reactivity in a sample matrix caused by drug non-specific binding interactions.
    Type: Application
    Filed: July 10, 2019
    Publication date: January 16, 2020
    Inventors: Giane SUMNER, Jihua CHEN, Michael PARTRIDGE, Albert TORRI, Manoj RAJADHYAKSHA
  • Competitive ligand binding assay for detecting neutralizing antibodies
    Patent number: 10261094
    Abstract: A immunogenicity assay for detecting the presence of neutralizing antibodies to a biotherapeutic protein wherein the biotherapeutic protein has been administered to a patient in need, comprising the steps of (a) obtaining a sample from the patient; (b) incubating the sample in the presence of a capture reagent; and (c) adding a detecting reagent, wherein a decreased signal relative to a control sample indicates the presence of a neutralizing antibody to the biotherapeutic agent.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: April 16, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Manoj Rajadhyaksha, Michael Partridge, Albert Torri
  • COMPETITIVE LIGAND BINDING ASSAY FOR DETECTING NEUTRALIZING ANTIBODIES
    Publication number: 20160252520
    Abstract: A immunogenicity assay for detecting the presence of neutralizing antibodies to a biotherapeutic protein wherein the biotherapeutic protein has been administered to a patient in need, comprising the steps of (a) obtaining a sample from the patient; (b) incubating the sample in the presence of a capture reagent; and (c) adding a detecting reagent, wherein a decreased signal relative to a control sample indicates the presence of a neutralizing antibody to the biotherapeutic agent.
    Type: Application
    Filed: October 30, 2014
    Publication date: September 1, 2016
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Manoj RAJADHYAKSHA, Gary SHYU, Camille GEORGAROS, Michael PARTRIDGE, Albert TORRI